CEROWCERo Therapeutics Holdings Inc. Warrants

NAS · US · cero.bio

0.0017USD-32.00%Mkt Cap: —P/E: —4d ago

CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T …

Key Statistics

Company

Market Cap—

Enterprise Value—

Revenue (TTM)—

Gross Profit—

Net Income (TTM)-19.92M $

Revenue/Share—

Last Price0.0017 USD

Fiscal Year End—

MR Quarter—

Employees8

CountryUS

Sector—

Industry—

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA—

EV/Revenue—

P/S—

P/B-0.00

EPS (TTM)—

EPS (Forward)—

52W Range

0.00117% of range0.0093

52W High0.0093 USD

52W Low0.0011 USD

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE365.75%

ROA-547.09%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-16.08M $

CapEx (TTM)—

FCF Margin—

FCF Yield—

Net Debt—

Net Debt/EBITDA—

Balance Sheet

Debt/Equity-0.13

Current Ratio—

Quick Ratio—

Book Value/Sh-0.4580 USD

Cash/Share—

Dividends

Fwd Div Rate—

Trail. Div Rate0.0000 USD

Div. Yield—

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.—

Float—

Insiders—

Institutions—

Technical

SMA 50—

SMA 200—

Beta—

S&P 52W Chg18.16%

Avg Vol (30d)17.11K

Avg Vol (10d)—

Technical Indicators

RSI (14)—

MACD—

MACD Signal—

MACD Hist.—

BB Upper—

BB Middle—

BB Lower—

BB Width—

ATR (14)—

Vol Ratio (20d)—